Prelude Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview
08/08/2025 17:01
Prelude Therapeutics Inc PRLD.OQ PRLD.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025 ​LSEG's mean analyst estimate for Prelude Therapeutics Inc is for a loss of 44 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Wall Street's median 12-month price target for Prelude Therapeutics Inc is $4.50, about 81% above its last closing price of $0.86 Previous quarterly performance (using preferred earnings measure in US dollars). ​
| QUARTER ENDING | STARMINESMARTESTIMATEÂŪ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.47 | -0.47 | -0.42 | Beat | 10.3 |
| Dec. 31 2025 | -0.46 | -0.38 | Beat | 18 | |
| Sep. 30 2024 | -0.47 | -0.47 | -0.43 | Beat | 8.9​ |
| Jun. 30 2024 | -0.43 | -0.43 | -0.46 | Missed | -7 |
| ​​Mar. 31 2024 | -0.48 | -0.48 | -0.42 | Beat | 13.4 |
| Dec. 31 2023 | -0.49 | -0.49 | -0.46 | Beat | 6.1​ |
| Sep. 30 2023 | -0.58 | -0.58 | -0.45 | Beat | 22.7 |
| Jun. 30 2023 | -0.64 | -0.63 | -0.54 | Beat | 14.7 |
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview